Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma
The primary purpose of the study is to determine the proportion of patients without progression at 6-months in patients with unresectable Stage III or Stage IV melanoma who are taking RTA 402.
Malignant Melanoma
DRUG: RTA 402 Dose1|DRUG: RTA 402 Dose2
To determine the proportion of patients without progression at 6 months in patients with unresectable Stage III or Stage IV melanoma treated with RTA 402.
To determine the overall response rate and duration of responses
This is a phase II, open label, randomized study in patients with unresectable Stage III or Stage IV malignant melanoma. Patients will be randomly assigned to two different doses of RTA 402 administered orally once daily for 28 consecutive days, for up to 18 months.